ESPR
Esperion Therapeutics, Inc.
$3.13
+0.00
(+0.00%)
Mkt Cap
650.75M
Volume
6,694,912
52W Range
0.79-4.18
Sector
Healthcare
Beta
0.91
EPS (TTM)
-0.02
P/E Ratio
-33.91
Revenue (TTM)
418.24M
Rev Growth (5Y)
+12.1%
EPS Growth (5Y)
N/A
Company Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 403.13M | 332.31M | 116.33M | 75.47M | 78.45M | 227.55M | 148.36M | 184.47M | 0 | 0 | 0 | 0 |
| Net Income | (22.68M) | (51.74M) | (209.25M) | (233.66M) | (269.11M) | (143.55M) | (97.17M) | (201.81M) | (166.99M) | (74.98M) | (49.78M) | (36.38M) |
| EPS | -0.11 | -0.28 | -2.03 | -4.33 | -11.03 | -6.05 | -4.02 | -7.54 | -6.98 | -3.33 | -2.26 | -2.22 |
| Free Cash Flow | (13.09M) | (23.97M) | (135.49M) | (174.83M) | (263.81M) | (98.55M) | (71.29M) | (148.79M) | (131.32M) | (47.82M) | N/A | N/A |
| FCF / Share | -0.06 | -0.13 | -1.31 | -2.63 | -9.13 | -3.59 | -2.63 | -5.56 | -5.49 | -2.12 | N/A | N/A |
| Operating CF | (13.09M) | (23.65M) | (135.49M) | (174.83M) | (263.81M) | (85.18M) | (70.34M) | (148.64M) | (131.30M) | (47.73M) | N/A | N/A |
| Total Assets | 465.89M | 343.82M | 205.80M | 247.94M | 381.59M | 353.26M | 214.45M | 143.45M | 277.83M | 245.21M | N/A | N/A |
| Total Debt | 548.00M | 591.21M | 540.95M | 260.95M | 260.20M | 185.41M | 1.56M | 0 | 1.04M | 2.73M | N/A | N/A |
| Cash & Equiv | 167.85M | 144.76M | 82.25M | 124.78M | 208.89M | 304.96M | 166.13M | 36.97M | 34.47M | 38.16M | N/A | N/A |
| Book Value | (301.96M) | (388.72M) | (454.99M) | (323.78M) | (196.94M) | (96.13M) | 19.95M | (598.10M) | 244.69M | 228.60M | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | -4.87 | N/A | -0.68 | -0.33 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 80.10M | 168.45M | 87.31M | 82.39M | 65.00M | 69.11M | 51.63M | 73.83M | 137.74M | 32.25M | 33.97M | 25.79M |
| Net Income | (25.20M) | 61.83M | (31.33M) | (12.72M) | (40.45M) | (21.32M) | (29.52M) | (61.92M) | 61.02M | (56.34M) | (41.25M) | (49.94M) |
| EPS | -0.10 | 0.26 | -0.16 | -0.02 | -0.21 | -0.11 | -0.15 | -0.33 | 0.36 | -0.50 | -0.37 | -0.46 |
| Free Cash Flow | (27.91M) | 45.43M | (4.29M) | (31.42M) | (22.63M) | (34.95M) | (35.49M) | (7.28M) | 53.76M | (37.06M) | (19.32M) | (24.75M) |
| FCF / Share | -0.11 | 0.19 | -0.02 | -0.16 | -0.12 | -0.18 | -0.18 | -0.04 | 0.32 | -0.33 | -0.17 | -0.23 |
| Operating CF | (27.72M) | 45.24M | (4.29M) | (31.42M) | (22.63M) | (34.95M) | (35.33M) | (7.21M) | 53.83M | (37.06M) | (19.32M) | (24.75M) |
| Total Assets | 462.53M | 465.89M | 364.02M | 347.08M | 324.03M | 343.82M | 314.11M | 352.32M | 373.06M | 205.80M | 221.31M | 234.63M |
| Total Debt | 252.63M | 548.00M | 600.99M | 598.18M | 297.78M | 297.60M | 268.96M | 269.13M | 548.87M | 540.95M | 301.14M | 285.91M |
| Cash & Equiv | 156.16M | 167.85M | 92.45M | 86.06M | 114.63M | 144.76M | 144.72M | 189.30M | 226.61M | 82.25M | 114.83M | 138.47M |
| Book Value | (307.93M) | (301.96M) | (451.36M) | (433.51M) | (426.21M) | (388.72M) | (370.21M) | (344.22M) | (294.30M) | (454.99M) | (410.00M) | (371.98M) |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ESPR News
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ESPR Stock Surges 44% in a Month: Here's What You Need to Know
Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—PFLC, ESPR, LKSB, and MKC
Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Esperion Therapeutics, Inc. (NASDAQ: ESPR)
Shareholder Alert: Ademi LLP investigates whether Esperion Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders
ESPR Stock Alert: Halper Sadeh LLC is Investigating Whether Esperion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders
Archimed to take Esperion Therapeutics private in $1.1 billion deal
Esperion to be Acquired by ARCHIMED